$894 Million Settlement Against Pfizer for Bextra and Celebrex

What Happened? The litigation against Pfizer stemmed from claims that Bextra and Celebrex increased the risk and incidence of cardiovascular events in patients who were prescribed the medications primarily for arthritis-related pain. Seeger Weiss LLP, along with co-counsel, was one of the first firms to file Bextra and Celebrex related complaints against Pfizer in the […]

October 17, 2008

What Happened?

The litigation against Pfizer stemmed from claims that Bextra and Celebrex increased the risk and incidence of cardiovascular events in patients who were prescribed the medications primarily for arthritis-related pain. Seeger Weiss LLP, along with co-counsel, was one of the first firms to file Bextra and Celebrex related complaints against Pfizer in the United States and represented approximately 400 claimants. In 2005, Pfizer withdrew Bextra from the market, while Celebrex remained, but with a required Black Box safety warning regarding the risk of heart attacks and strokes.

How Was the Settlement Structured?

Seeger Weiss LLP founding partner Christopher A. Seeger, a member of the Plaintiffs’ Steering Committee in the Bextra and Celebrex Marketing Sales Practices and Product Liability Litigation, helped to shape the $894 million settlement which was announced by Pfizer on October 17, 2008.

In total, there were several thousand lawsuits filed against Pfizer because of Bextra and Celebrex related injuries and deaths. The settlement figure announced was split up to deal with the various claims that were brought against Pfizer:

  • $745 million went toward personal-injury lawsuits;
  • $60 million went to states regarding the Bextra marketing claims; and
  • $89 million was allocated to resolve the consumer-fraud cases.

What is the Current Status of Bextra and Celebrex Lawsuits?

A Securities Class Action Against Pfizer Settled for $486 Million

In 2016, a related securities class action lawsuit filed by investors in 2004, was settled for $486 million. The investors claimed that Pfizer concealed information regarding studies of Bextra and Celebrex, that demonstrated the drugs might increase the risk of heart attacks and strokes. Once the studies were released to the public, and Bextra was pulled from the market, Pfizer’s share price dropped, and investors suffered losses.

Related News

March 13, 2024
The Legal 500 recognizes Seeger Weiss as a Top Firm and Inducts Co-Founder Chris Seeger into the Hall of Fame

Seeger Weiss is pleased to announce that the firm was named one of The Legal 500 Top Product Liability, Mass Tort, and Class Action Firms. Co-founder Chris Seeger was also named to The Legal 500 Plaintiff Hall of Fame. These esteemed recognitions showcase Seeger Weiss’ and Chris Seeger’s unwavering dedication to ensuring corporate responsibility and […]

Read More
February 29, 2024
Seeger Weiss’ Founding Partner Chris Seeger and Senior Partner Dave Buchanan discussed the 3M settlement and other key wins with Law360

Seeger Weiss was recently recognized as Law360’s 2023 Product Liability Group of the Year, after the firm secured multiple litigation victories, including a groundbreaking $6 billion deal to settle the massive litigation brought by veterans and service members, who claimed that 3M’s combat earplugs caused harm to their hearing. Between 1999 and 2015, 3M knowingly […]

Read More
February 23, 2024
Thirteen Seeger Weiss Partners Selected for Lawdragon 500 Leading Plaintiff Consumer Lawyers List

Seeger Weiss is proud to announce that Lawdragon recognized 13 partners — Chris Seeger, Stephen Weiss, David Buchanan, Parvin Aminolroaya, Shauna Itri, Matt Pawa, Jennifer Scullion, Chris Ayers, Jeffrey Grand, Scott Alan George, Diogenes Kekatos, Michael Rosenberg, and Caleb Seeley — on the 2024 Lawdragon 500 Leading Plaintiff Consumer Lawyers list. The Lawdragon 500 Leading […]

Read More